International Stem Cell Corp., a biotech company developing stem cell based therapies, today announced the pricing of a public offering. Consisting of one share of common stock and one Series A Warrant to purchase one share of our common stock at an exercise price of $0.15 per share, each of the 20,000,000 units are being sold at $0.15.
The company is also offering up to 20,000,000 Series B Warrants, each to purchase one unit. Purchasers will receive one Series B Warrant for each unit purchased. Additional details on the Series B Warrants can be found in today's press release. Each Series A Warrant will be immediately exercisable at an initial exercise price of $0.15 per share. The Series A Warrants will expire on the fifth anniversary of the initial date of issuance.
International Stem Cell Corp. plans to use the net proceeds from this offering to fund its research and development activities, as well as for general working capital purposes.
Roth Capital Partners acted as the sole placement agent for the offering. The securities are being offered by the company pursuant to a registration statement on Form S-1 filed with the SEC. A final prospectus relating to the offering can be found on the SEC's website located at sec.gov. Electronic copies of the prospectus also may be obtained from Roth Capital Partners, LLC Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, at 800-678-9147 begin_of_the_skype_highlighting 800-678-9147 FREE end_of_the_skype_highlighting.
For more information, visit internationalstemcell.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net